A comparison between a gastroesophageal reflux disease questionnaire-based algorithm and multichannel intraluminal impedance-pH monitoring for the treatment of gastroesophageal reflux-induced chronic cough.

IF 3.3 3区 医学 Q2 RESPIRATORY SYSTEM Therapeutic Advances in Respiratory Disease Pub Date : 2024-01-01 DOI:10.1177/17534666231220817
Wanzhen Li, Tongyangzi Zhang, Wenhua Gu, Wenbo Shi, Shengyuan Wang, Yiqing Zhu, Cuiqin Shi, Li Yu, Xianghuai Xu
{"title":"A comparison between a gastroesophageal reflux disease questionnaire-based algorithm and multichannel intraluminal impedance-pH monitoring for the treatment of gastroesophageal reflux-induced chronic cough.","authors":"Wanzhen Li, Tongyangzi Zhang, Wenhua Gu, Wenbo Shi, Shengyuan Wang, Yiqing Zhu, Cuiqin Shi, Li Yu, Xianghuai Xu","doi":"10.1177/17534666231220817","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Empiric therapy with multichannel intraluminal impedance-pH monitoring (MII-pH) has been used for the initial treatment of gastroesophageal reflux-induced chronic cough (GERC). However, an algorithm based on the gastroesophageal reflux disease questionnaire (GerdQ) has the potential to achieve a simple, structured, and effective treatment approach for patients with GERC.</p><p><strong>Objectives: </strong>This study compared the efficacy of anti-reflux therapy based on GerdQ (new structured pathway, NSP) with medical treatment after MII-pH examination (ordinary clinical pathway, OCP) in the management of GERC.</p><p><strong>Design: </strong>For the NSP, we adapted the GerdQ score to establish the basis for a treatment algorithm. For the OCP, treatment was determined using the MII-pH examination results.</p><p><strong>Methods: </strong>The non-inferiority (NI) hypothesis was used to evaluate NSP <i>versus</i> OCP.</p><p><strong>Results: </strong>Overall, the NSP and OCP-based therapeutic algorithms have similar efficacy for GERC [NI analysis: 95% confidence interval (CI), -4.97 to 17.73, <i>p</i> = 0.009; superiority analysis: <i>p</i> = 0.420]. Moreover, the cough symptom scores and cough threshold improved faster in the NSP group than in the OCP group at week 8 (<i>p</i> < 0.05). In the subgroup analyses using the GerdQ and GerdQ impact scale (GIS) scores, patients with low-likelihood GERC (GerdQ < 8) were more likely to benefit from OCP (NI analysis: 95% CI, -19.73 to 18.02, <i>p</i> = 0.213). On the other hand, in patients with high-likelihood and low-reflux impact GERC patients (GerdQ > 8 and GIS < 4), the NSP arm was not inferior to the standard treatment of OCP (NI analysis: 95% CI, -8.85 to 28.21%, <i>p</i> = 0.04; superiority analysis: <i>p</i> = 0.339), indicating that GerdQ- and GIS-guided diagnosis and management of patients with GERC could be an alternative to MII-pH management, especially in settings with reduced medical resources.</p><p><strong>Conclusions: </strong>The use of the GerdQ algorithm should be considered when handling patients with GERC in the primary care setting.</p><p><strong>Trial registration: </strong>This research was registered in the Chinese Clinical Trials Registry (ChiCTR-ODT-12001899).</p>","PeriodicalId":22884,"journal":{"name":"Therapeutic Advances in Respiratory Disease","volume":"18 ","pages":"17534666231220817"},"PeriodicalIF":3.3000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10771753/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Therapeutic Advances in Respiratory Disease","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/17534666231220817","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"RESPIRATORY SYSTEM","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Empiric therapy with multichannel intraluminal impedance-pH monitoring (MII-pH) has been used for the initial treatment of gastroesophageal reflux-induced chronic cough (GERC). However, an algorithm based on the gastroesophageal reflux disease questionnaire (GerdQ) has the potential to achieve a simple, structured, and effective treatment approach for patients with GERC.

Objectives: This study compared the efficacy of anti-reflux therapy based on GerdQ (new structured pathway, NSP) with medical treatment after MII-pH examination (ordinary clinical pathway, OCP) in the management of GERC.

Design: For the NSP, we adapted the GerdQ score to establish the basis for a treatment algorithm. For the OCP, treatment was determined using the MII-pH examination results.

Methods: The non-inferiority (NI) hypothesis was used to evaluate NSP versus OCP.

Results: Overall, the NSP and OCP-based therapeutic algorithms have similar efficacy for GERC [NI analysis: 95% confidence interval (CI), -4.97 to 17.73, p = 0.009; superiority analysis: p = 0.420]. Moreover, the cough symptom scores and cough threshold improved faster in the NSP group than in the OCP group at week 8 (p < 0.05). In the subgroup analyses using the GerdQ and GerdQ impact scale (GIS) scores, patients with low-likelihood GERC (GerdQ < 8) were more likely to benefit from OCP (NI analysis: 95% CI, -19.73 to 18.02, p = 0.213). On the other hand, in patients with high-likelihood and low-reflux impact GERC patients (GerdQ > 8 and GIS < 4), the NSP arm was not inferior to the standard treatment of OCP (NI analysis: 95% CI, -8.85 to 28.21%, p = 0.04; superiority analysis: p = 0.339), indicating that GerdQ- and GIS-guided diagnosis and management of patients with GERC could be an alternative to MII-pH management, especially in settings with reduced medical resources.

Conclusions: The use of the GerdQ algorithm should be considered when handling patients with GERC in the primary care setting.

Trial registration: This research was registered in the Chinese Clinical Trials Registry (ChiCTR-ODT-12001899).

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
基于胃食管反流病调查问卷的算法与多通道腔内阻抗-pH 监测在治疗胃食管反流引起的慢性咳嗽方面的比较。
背景:多通道腔内阻抗-pH 监测(MII-pH)经验疗法一直被用于胃食管反流引起的慢性咳嗽(GERC)的初始治疗。然而,基于胃食管反流病问卷(GerdQ)的算法有可能为 GERC 患者提供一种简单、结构化且有效的治疗方法:本研究比较了基于 GerdQ 的抗反流治疗(新结构化路径,NSP)与 MII-pH 检查后的药物治疗(普通临床路径,OCP)在 GERC 治疗中的疗效:对于 NSP,我们对 GerdQ 评分进行了调整,为治疗算法奠定了基础。对于 OCP,我们根据 MII-pH 检查结果决定治疗方法:方法:采用非劣效性(NI)假设对 NSP 和 OCP 进行评估:总体而言,基于 NSP 和 OCP 的治疗算法对 GERC 具有相似的疗效[NI 分析:95% 置信区间 (CI),-4.97 至 17.73,p = 0.009;优越性分析:p = 0.420]。此外,在第 8 周时,NSP 组的咳嗽症状评分和咳嗽阈值的改善速度快于 OCP 组(P = 0.213)。另一方面,在高可能性和低反流影响的 GERC 患者中(GerdQ > 8 和 GIS p = 0.04;优越性分析:p = 0.339),这表明在 GerdQ 和 GIS 指导下对 GERC 患者进行诊断和管理可以替代 MII-pH 管理,尤其是在医疗资源减少的情况下:结论:在基层医疗机构处理 GERC 患者时,应考虑使用 GerdQ 算法:本研究已在中国临床试验注册中心注册(ChiCTR-ODT-12001899)。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
6.90
自引率
0.00%
发文量
57
审稿时长
15 weeks
期刊介绍: Therapeutic Advances in Respiratory Disease delivers the highest quality peer-reviewed articles, reviews, and scholarly comment on pioneering efforts and innovative studies across all areas of respiratory disease.
期刊最新文献
Potential of phosphodiesterase 4B inhibition in the treatment of progressive pulmonary fibrosis. A real-world study to evaluate effectiveness of mepolizumab in treating severe asthma in Taiwan (REMIT). Association between albumin corrected anion gap and in-hospital mortality in critically ill patients with chronic obstructive pulmonary disease. Sleep and breathing in children with Joubert syndrome and a review of other rare congenital hindbrain malformations. The impact of quantitative platform on candidacy for bronchoscopic lung volume reduction: a multi-center retrospective cohort study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1